Oxford BioMedica licences Hi-8 PrimeBoost vaccines technology to Emergent BioSolutions in $20 million accord
UK-based gene therapy firm Oxford BioMedica has signed a licensing deal with Emergent Product Development Germany GmbH, a wholly-owned subsidiary of US company Emergent BioSolutions, granting the latter non-exclusive rights to its Hi-8 PrimeBoost technology patents and a sub-licence under poxvirus patents licensed to the company for the development and commercialization of vaccines and therapeutics targeting eight infectious diseases, including tuberculosis.
Under the terms of the agreement Emergent (which this week also announced that it is buying Trubion Pharma to expand its oncology and autoimmunity portfolio; The Pharma Letter August 16) will pay an upfront licensing fee of $1 million, potential milestones of up to $20.4 million and undisclosed royalties on sales.
TB vaccine a target
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze